focus -WSS

focus

author：explore 2025-09-29 10:31:29 - browse：885

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Dementia risk linked to living in disadvantaged areas: Study

hotspot

knowledge

WSS

Sanders wants to replace patents with prizes for drug inventions

How a Boston hospital is priming medical residents to use GPT

Hormonal contraceptives don’t actually treat endometriosis

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Wikipedia

focus

focus

23andMe had bad news about my health. I wish a person had delivered it

Scientists grapple with ethics of stem cell research

Wildfire smoke exposes gaps in outdoor worker protections

Superbugs, antibiotic resistance get scrutiny in congress

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Companies helping big Covid

State Dept. review finds Biden bears some blame for Afghanistan failures

US jobless claims fall again as labor market continues to flash strength

Apple is now the first public company to be valued at $3 trillion

One Duchenne patient's bittersweet hope for new treatment

explore

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Digital health funding stays low as a new reality sets in

Grail's uphill battle for Medicare to cover its cancer screening test

Sanders wants to replace patents with prizes for drug inventions

How a Boston hospital is priming medical residents to use GPT

'CMA Fest' 2023: How to watch, who is performing and more

hotspot

knowledge

knowledge

focus